Myriad Genetics (MYGN) Net Cash Flow (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of Net Cash Flow data on file, last reported at -$25.2 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$25.2 million, down 129.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.4 million (up 642.22% YoY), and the FY2025 annual result was $38.6 million, up 237.86% from the prior year.
• Net Cash Flow fell to -$25.2 million in Q1 2026 per MYGN's latest filing, from -$3.6 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $71.1 million in Q3 2025 and troughed at -$92.6 million in Q1 2022.
• A 5-year average of -$7.8 million and a median of -$3.6 million in 2025 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 1294.12% in 2025 and fell as far as 1178.57% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$45.0 million in 2022, then jumped by 222.67% to $55.2 million in 2023, then sank by 94.93% to $2.8 million in 2024, then sank by 228.57% to -$3.6 million in 2025, then tumbled by 600.0% to -$25.2 million in 2026.
• Business Quant data shows MYGN's Net Cash Flow at -$25.2 million in Q1 2026, -$3.6 million in Q4 2025, and $71.1 million in Q3 2025.